BACKGROUND: Type 1 neurofibromatosis (NF1) is a genetic disease characterized by neoplastic and not neoplastic disorders, involving tissues of neuroectodermal or mesenchymal origin. The mainly involved districts are skin, central nervous system, and eye, and there is a wide range of severity of clinical presentations. DATA SOURCES: Abdominal manifestations of NF1 comprehend five categories of tumors: neurogenic with neurofibromas, malignant peripheral nerve sheath tumors and ganglioneuromas, neuroendocrine with pheochromocytomas and carcinoids, non-neurogenic gastrointestinal stromal tumors, i.e., GISTs, and embryonal tumors and miscellaneous. CONCLUSIONS: Early diagnosis of these abdominal manifestations is very important given the risk of malignancy, organic complications such as in the case of pheochromocytomas or hemorrhagic-obstructive complications such as in the case of the tumors of the gastrointestinal tract (GISTs and neurofibromas). The importance of an annual clinical evaluation on the part of a multidisciplinary pool of clinicians in highly specialized centers allows early detection of complications and of neoplastic transformation.
BACKGROUND:Type 1 neurofibromatosis (NF1) is a genetic disease characterized by neoplastic and not neoplastic disorders, involving tissues of neuroectodermal or mesenchymal origin. The mainly involved districts are skin, central nervous system, and eye, and there is a wide range of severity of clinical presentations. DATA SOURCES: Abdominal manifestations of NF1 comprehend five categories of tumors: neurogenic with neurofibromas, malignant peripheral nerve sheath tumors and ganglioneuromas, neuroendocrine with pheochromocytomas and carcinoids, non-neurogenic gastrointestinal stromal tumors, i.e., GISTs, and embryonal tumors and miscellaneous. CONCLUSIONS: Early diagnosis of these abdominal manifestations is very important given the risk of malignancy, organic complications such as in the case of pheochromocytomas or hemorrhagic-obstructive complications such as in the case of the tumors of the gastrointestinal tract (GISTs and neurofibromas). The importance of an annual clinical evaluation on the part of a multidisciplinary pool of clinicians in highly specialized centers allows early detection of complications and of neoplastic transformation.
Authors: D Viskochil; A M Buchberg; G Xu; R M Cawthon; J Stevens; R K Wolff; M Culver; J C Carey; N G Copeland; N A Jenkins Journal: Cell Date: 1990-07-13 Impact factor: 41.582
Authors: T De Raedt; H Brems; P Wolkenstein; D Vidaud; S Pilotti; F Perrone; V Mautner; S Frahm; R Sciot; E Legius Journal: Am J Hum Genet Date: 2003-03-26 Impact factor: 11.025
Authors: Angela D Levy; Nandini Patel; Robert M Abbott; Nancy Dow; Markku Miettinen; Leslie H Sobin Journal: AJR Am J Roentgenol Date: 2004-12 Impact factor: 3.959
Authors: C Andrew Kistler; Jennifer M Johnson; Jordan M Winter; Jeffrey P Baliff; Ali A Siddiqui; Ashwin R Sama Journal: J Gastrointest Oncol Date: 2014-12
Authors: Abbas Agaimy; Bruno Märkl; Julia Kitz; Peter H Wünsch; Hans Arnholdt; Laszlo Füzesi; Arndt Hartmann; Runjan Chetty Journal: Virchows Arch Date: 2010-02-13 Impact factor: 4.064
Authors: M R Zandomeni; M Chahdi Beltrame; M de Santibañes; O Mazza; J Pekolj; E de Santibañes; R Sanchez Claria Journal: J Gastrointest Cancer Date: 2018-03
Authors: Thomas Artur Werner; Feride Kröpil; Martin Olaf Schoppe; Patric Kröpil; Wolfram Trudo Knoefel; Andreas Krieg Journal: World J Gastroenterol Date: 2014-06-28 Impact factor: 5.742